Renal Impairment · Chapter 1
The Renal Decision Framework
How to think about psychotropic prescribing when the kidneys are the constraint — which number to trust, which drugs actually accumulate, and when a dose genuinely needs to change.
Bottom Line Up Front
The 30-second version
- Depression affects roughly a quarter of CKD patients — far above the general population — so "just avoid the drug" usually isn't an option. You have to dose through the kidney disease, safely.
- Most psychotropics are cleared by the liver, so renal impairment changes the dose for a minority of agents. The skill is identifying which ones — not reflexively reducing everything.
- The highest-stakes renal psychotropics are lithium and the gabapentinoids (gabapentin, pregabalin): renally cleared, narrow margin, and the ones that quietly accumulate to toxicity.
- The field is mid-shift on which kidney number to use. Legacy drug labels were written around Cockcroft-Gault creatinine clearance, but 2024 FDA guidance and the National Kidney Foundation now point to the race-free CKD-EPI 2021 eGFR. Match the number to the label your drug actually used.
Which Number to Trust (60-Second Version)
Two estimates of kidney function sit on every chart, and they are not interchangeable. eGFR — what your lab reports, now via the race-free CKD-EPI 2021 equation — is normalized to a standard body size (1.73 m²) and is what stages chronic kidney disease. Cockcroft-Gault estimates creatinine clearance (in mL/min, not body-size-normalized) and, for roughly fifty years, was the formula most drug labels used to set their renal dose thresholds.
The old teaching was blunt: "use Cockcroft-Gault for drug dosing." That is now in active transition. 2024 FDA guidance for industry recommends eGFR over Cockcroft-Gault for characterizing pharmacokinetics in renal impairment, and the November 2024 National Kidney Foundation consensus recommends moving medication decisions to the race-free CKD-EPI 2021 eGFR — adjusted back to the individual's body surface area (de-indexed to plain mL/min) in very small or very large patients, where the 1.73 m² normalization distorts the dose.
The practical rule survives the change: match the estimate to the label. Most psychotropic labels are old, so their cutoffs are Cockcroft-Gault creatinine clearance; newer agents increasingly state eGFR. When the two numbers diverge — the very elderly, very small, very large, or anyone whose function is unstable — that divergence is itself the signal to slow down and look closer.
Cockcroft-Gault, for reference
CrCl (mL/min) = [(140 − age) × weightkg] ÷ (72 × serum creatininemg/dL) × 0.85 if female. Overestimates clearance in obesity and edema (use adjusted body weight); underestimates in the very elderly; and assumes a stable creatinine — which is exactly what an acutely ill patient does not have.
The Stages That Matter
| GFR category | eGFR (mL/min/1.73m²) | Description |
|---|---|---|
| G1 | ≥ 90 | Normal or high (CKD only with other damage markers) |
| G2 | 60–89 | Mildly decreased (CKD only with other markers) |
| G3a | 45–59 | Mildly to moderately decreased |
| G3b | 30–44 | Moderately to severely decreased |
| G4 | 15–29 | Severely decreased |
| G5 | < 15 | Kidney failure |
KDIGO stages CKD by Cause, GFR category, and Albuminuria (the "CGA" system; albuminuria runs A1 <30, A2 30–300, A3 >300 mg/g). For prescribing, the GFR number drives most decisions — and most psychotropic label thresholds cluster at roughly <60, <30, and <15 mL/min, which maps loosely onto G3a, G4, and G5/dialysis. Knowing those three break-points is most of the job.
The Core Principle: The Number Is About the Patient, Not the Drug
This is the idea to carry out of the chapter. The eGFR tells you how well this patient filters — it tells you nothing about whether this drug depends on the kidney. A medication needs renal adjustment only to the extent that the kidney clears the active drug, or an active or toxic metabolite. A hepatically metabolized agent with inactive metabolites usually needs no change even at G4.
So the question at the point of care is not "Is the kidney impaired?" — it's "How much does this particular drug rely on the kidney, and how narrow is its margin if it accumulates?" Three things complicate the simple picture:
- Active metabolites hide the risk — the parent looks fine while a renally-cleared metabolite climbs (risperidone → paliperidone).
- Uremia shifts protein binding — low albumin and uremic displacement raise the free fraction of highly bound drugs (valproate, phenytoin), so a "therapeutic" total level understates active drug.
- The number must be stable to mean anything — in acute kidney injury the eGFR is a lagging fiction (see below).
The Three Dose-Adjustment Triggers
A psychotropic needs a renal dose change only when all three of the following are true. If any one is missing, you usually leave the dose alone — which is why "renal impairment" is not a blanket instruction to reduce every drug.
| Trigger | The question | If "no"… |
|---|---|---|
| 1. Renal route | Is a clinically meaningful fraction of the active drug (or an active/toxic metabolite) excreted unchanged by the kidney? | Hepatic clearance with inactive metabolites → usually no adjustment. |
| 2. Narrow margin | Is the therapeutic window tight enough that accumulation causes real harm? | A wide-margin drug tolerates some accumulation. |
| 3. Threshold crossed | Is kidney function low enough — or changing fast enough — to pass the label's adjustment cut-point? | Above the threshold → standard dosing, monitor. |
Lithium and the gabapentinoids tick all three boxes, every time — which is why they dominate this course. Most SSRIs tick at most one.
Which Psychotropics Accumulate (Orientation)
This chapter gives you the map, not the agent-by-agent dose tables — those live in the member chapters. At a high level:
| Tier | Agents (orientation only) |
|---|---|
| Highest concern renally cleared + narrow margin |
Lithium — the defining renal psychotropic: both renally cleared and nephrotoxic, and exquisitely sensitive to volume status. Gabapentin & pregabalin — renally eliminated, dose-dependent sedation, falls, and accumulation. |
| Watch renal route or active renal metabolite |
Paliperidone (directly renally excreted — the trap), risperidone (active metabolite is paliperidone), venlafaxine / desvenlafaxine (accumulate), topiramate, levomilnacipran (and milnacipran, ~55% renal — fibromyalgia, common in CKD), memantine, bupropion (parent hepatic, but renally-cleared active metabolites), and amisulpride (predominantly renal; limited US availability). |
| Generally lower hepatic, inactive metabolites |
Most SSRIs (sertraline, fluoxetine, paroxetine, citalopram, escitalopram), most TCAs, olanzapine, quetiapine, aripiprazole, clozapine. "Lower" is not "ignore" — start low and titrate slowly for pharmacodynamic sensitivity and protein-binding shifts. |
Notice the pattern: the danger concentrates in a short list. Get lithium, the gabapentinoids, and the renally-cleared metabolite traps right, and you have managed most of the real risk.
AKI vs CKD: A Stable Number vs a Moving Target
In chronic kidney disease the function is stable or drifts slowly, so the eGFR is a usable dosing anchor. Acute kidney injury is different: the estimating equations assume a steady-state creatinine, and in AKI the creatinine lags the true filtration by a day or more. A near-normal number can badly overestimate a kidney that is already failing.
So in AKI, do not trust a single eGFR. Assume function is worse than the number and still falling; hold or minimize renally-cleared, narrow-margin agents — lithium above all, which can both cause and be worsened by volume depletion and AKI; recheck function frequently; and dose to the trajectory, not the snapshot. For orientation, KDIGO defines AKI as a creatinine rise of ≥ 0.3 mg/dL within 48 h, a rise to ≥ 1.5× baseline within 7 days, or urine output < 0.5 mL/kg/h for ≥ 6 h.
The traffic runs both ways. Psychotropics don't only accumulate in a failing kidney — some can precipitate the injury. In older adults, starting an atypical antipsychotic was associated with a higher 90-day risk of AKI hospitalization (relative increase large, absolute risk low), via hypotension, acute urinary retention, and NMS/rhabdomyolysis. Keep that bidirectional picture in mind when a frail, elderly CKD patient starts an antipsychotic.
Dialyzability: What the Machine Removes
A drug is efficiently removed by hemodialysis when four properties line up: small molecular weight (< 500 Da), low protein binding (only free drug crosses the membrane), water solubility (the dialysate is aqueous), and a low volume of distribution (< 1 L/kg — a large Vd means the drug is sequestered in tissue, out of the dialyzer's reach).
| Profile | Behavior in dialysis |
|---|---|
| Readily dialyzed small, unbound, water-soluble, low Vd | Lithium is the textbook case — the basis for hemodialysis in severe lithium toxicity, and a session can drop the level enough to require re-dosing. Gabapentin & pregabalin are substantially removed and need a supplemental dose after HD. |
| Minimally dialyzed highly protein-bound, large Vd | Most antipsychotics and antidepressants. Dialysis neither rescues an overdose nor mandates a post-session top-up. |
The practical move for a dialyzable agent: time the dose after the session and know whether a post-dialysis supplement is required. Agent-level specifics are in the dialysis chapter.
The Action Ladder
eGFR ≥ 60 (G1–G2), stable
Proceed. For most psychotropics, no renal dose change; standard initiation and monitoring.
eGFR 30–59 (G3a–G3b)
Run the three triggers on the specific agent. For lithium and the gabapentinoids, reduce and monitor (levels and clinically). For renally-cleared metabolite drugs (paliperidone, venlafaxine), reduce per label. Start low, titrate slowly, and recheck function.
eGFR 15–29 (G4)
Avoid or substantially reduce renally-cleared narrow-margin agents; prefer a hepatically-cleared alternative where one exists. Involve pharmacy/nephrology for lithium; monitor levels wherever a meaningful target exists.
eGFR < 15 (G5) or on dialysis
Specialist territory. Dose to dialyzability and residual function; lithium is generally avoided or managed with extreme caution and post-dialysis dosing. See the dialysis chapter for agent-specific timing.
Clinical Pearls
Pearls
- Don't reduce everything. Most psychotropics are hepatically cleared; renal impairment is a reason to scrutinize a short list, not to halve every dose on the chart.
- Lithium is its own category. The one drug that is both renally cleared and nephrotoxic, and the one most sensitive to volume — NSAIDs, ACE-inhibitors/ARBs, thiazides, and dehydration all push levels up. (Full treatment in the lithium chapters.)
- Check whether the parent or the metabolite is the actor. Risperidone's active moiety is renally-cleared paliperidone; bupropion's hydroxy metabolite is renally cleared. The label may adjust for a metabolite you're not thinking about.
- Uremia unmasks free drug. For highly protein-bound agents (valproate, phenytoin), a normal total level can sit on top of a high free level. Interpret levels with the albumin and the urea in view.
- Match the kidney number to the label. Legacy psychotropic labels = Cockcroft-Gault CrCl; newer labels = CKD-EPI eGFR. Don't apply a threshold derived from one estimate to a number produced by the other — least of all at the extremes of body size.
- One eGFR in an unstable patient is fiction. In AKI, dose to the trajectory, not the printout.
- CKD amplifies QTc risk — budget for it. Reduced repolarization reserve, the electrolyte shifts of kidney disease (low K⁺, Mg²⁺, Ca²⁺), and accumulation of renally-eliminated QT-prolonging agents stack together, and the AHA names inadequate renal dose adjustment of QT drugs as a torsades risk. If you're starting a QT-active psychotropic (citalopram, escitalopram, antipsychotics) in CKD, lower your threshold for a baseline ECG — the drug-by-drug detail is in the Cardiac Impairment course in this series.
Red Flags — Stop and Reassess
Hold the agent and look closer
- Rising creatinine or falling urine output in a patient on lithium — or any renally-cleared, narrow-margin drug. Suspect accumulation; hold and reassess.
- Symptoms of lithium toxicity (new tremor, GI upset, ataxia, confusion) regardless of a "therapeutic" level — the serum level lags the tissue burden.
- A renally-cleared agent newly stacked with an NSAID, ACE-inhibitor/ARB, or diuretic in a CKD patient.
- New AKI, volume depletion, or iodinated-contrast exposure in a patient on an accumulating psychotropic.
- Falling sodium after starting a serotonergic antidepressant (SSRI/SNRI) — SIADH is the other electrolyte trap, and CKD already impairs free-water handling. Check a sodium within the first weeks, especially in older patients.
Patient Counseling Script
Plain-language script
"This medication is cleared by your kidneys, so we've set the dose with your kidney function in mind. If your kidneys are working harder than usual — if you get dehydrated, have a stomach bug, or start a new water pill or anti-inflammatory like ibuprofen — the level in your blood can climb. So drink normally, tell us before you start any new medicine, and call us or seek care if you feel shaky, unsteady, unusually drowsy or confused, or you're passing much less urine than normal. Please don't stop this medication on your own without talking to us first."
EMR / Documentation Template
References
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–S314.
- Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race (CKD-EPI 2021). N Engl J Med. 2021;385(19):1737–1749.
- U.S. Food & Drug Administration. Pharmacokinetics in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing: Guidance for Industry. 2024.
- St. Peter WL, et al. Moving forward from Cockcroft-Gault creatinine clearance to race-free eGFR to improve medication-related decision-making in adults: NKF Workgroup consensus. Am J Health-Syst Pharm. 2025;82(12):644 (published online ahead of print November 18, 2024).
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
- Mirrakhimov AE, Barbaryan A, Gray A, Ayach T. The role of renal replacement therapy in the management of pharmacologic poisonings. Int J Nephrol. 2016;2016:3047329 — dialyzability determinants (molecular weight, protein binding, volume of distribution, water solubility).
- Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement from the American Heart Association. Circulation. 2020;142(15):e214–e233 — inadequate renal dose adjustment of QT-prolonging drugs as a torsades risk factor.
- Hwang YJ, Dixon SN, Reiss JP, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med. 2014;161(4):242–248.
Last reviewed June 2026. Part of the Psychiatry Education Forum Academy; for clinician education — it supports, and does not replace, individual clinical judgment and current local protocols.
You have the framework. Now get the drug-by-drug answers.
This chapter taught you how to decide whether a psychotropic needs a renal adjustment at all. The member chapters give you the dose thresholds, level targets, and dialysis timing for every agent — starting with the one that matters most: lithium.
Educational use only. Refer to the sources cited above and current prescribing information for clinical decisions. Psychiatry Education Forum and authors assume no liability for use of this material.
Responses